$AVBP: ArriVent BioPharma Reports Positive Phase 1 Trial Data for ARR-217 ADC

$AVBP

$AVBP – ArriVent BioPharma Reports Positive Phase 1 Trial Data for ARR-217 ADC at ESMO

ArriVent BioPharma, Inc.

2026-10-26 00:00:00 UTC · SEC_8K · All $AVBP

?? Positive AI Sentiment (+6.8 / 10)

Demonstrated 44.8% ORR (13/29) and 93.1% DCR at 6 mg/kg dose in late-line CRC patients.
Across all doses (n=123), Grade 3+ TRAEs occurred in 30.1% of patients, improving to 20.4% at the 6 mg/kg dose.
Data presented orally at ESMO Congress 2026.

Observed market reaction after signal

4h -23.88% · Peak +14.29%